Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes

2021 ◽  
pp. 102251
Author(s):  
Engy M. Aboelnaga ◽  
Mohamed M. Aboelnaga ◽  
Hend MHR. Elkalla
Keyword(s):  
Type 2 Diabetes ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Therapy Effect ◽  
Cancer Prostate

scholarly journals Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania

BMJ Open ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. e045797
Author(s):  
Mingaile Drevinskaite ◽  
Ausvydas Patasius ◽  
Marius Kincius ◽  
Vincas Urbonas ◽  
Giedre Smailyte
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Cohort Study ◽  
Androgen Deprivation Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Androgen Deprivation ◽  
Gnrh Agonists ◽  
Increased Risk

ObjectivesTo examine the risk of type 2 diabetes in patients with prostate cancer and its association with androgen deprivation therapy (ADT).Design and participantsWe performed a retrospective cohort study of patients diagnosed with prostate cancer in the Lithuanian male population between 1 January 2003 and 31 December 2012 who were identified through the Lithuanian Cancer registry. All prostate cancer cases were linked to the National Health Insurance Fund database to obtain information regarding the diagnosis of diabetes mellitus and information on prescriptions of antiandrogens and gonadotropin-releasing hormone (GnRH) agonists. Patients with prostate cancer were followed up until the diagnosis of type 2 diabetes, or 31 December 2017, or date of death, whichever came first. Cox proportional hazard models were used to estimate the risk of type 2 diabetes in patients with prostate cancer with or without ADT exposure.Results27 580 men were diagnosed with prostate cancer, out of whom 14 502 (52.6%) did not receive ADT and 13 078 (47.4%) were treated with ADT. The incidence of type 2 diabetes for all patients with prostate cancer was 7.4/1000 person-years, for men on GnRH agonists 9.0/1000 person-years and 5.8/1000 person-years for men on antiandrogens. There was an increased risk of developing type 2 diabetes comparing ADT users and non-users (HR=1.49, 95% CI 1.34 to 1.66).ConclusionThis study showed an increased risk of diabetes in patients with prostate cancer treated with ADT in comparison to ADT-free patient cohort. GnRH agonist users showed higher susceptibility, while the group on antiandrogen monotherapy showed no such increase.

scholarly journals INFLUENCE OF NEURO-LIKE DYNAMIC ELECTRICAL STIMULATION ON NEURAL CONDUCTIVITY AND BASAL MICROCIRCULATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH PERIPHERAL NEUROPATHY

2021 ◽  
pp. 51-56
Author(s):  
V.А. Drobyshev ◽  
◽  
L.А. Shpagina ◽  
G.S. Logacheva ◽  
S.Yu. Ryavkin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Electrical Stimulation ◽  
Electric Pulse ◽  
Sensory Neuropathy ◽  
Controlled Study ◽  
Double Blind ◽  
Therapy Effect

The results of the study of the electric pulse therapy effect on the state of neural conductivity and microvasculature in 60 patients with moderate type 2 diabetes mellitus (DM2), accompanied by the peripheral sensory neuropathy, are presented. A comparative double-blind, placebo-controlled study of the inclusion of neuro-like dynamic electrical stimulation in the rehabilitation course was carried out. By the end of the rehabilitation course, the patients of the experimental group showed an increase in the velocity of excitation propagation along the tibial and peroneal nerves, restoration of the impaired spontaneous activity of deafferentated central neurons at the spinal and cerebral levels, and an improvement of basal microcirculation indices.

scholarly journals Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)

2015 ◽  
Vol 22 (1) ◽  
pp. 86-91
Author(s):  
M. V. Kim ◽  
S. A. Skoryukova ◽  
A. A. Bystrova ◽  
E. I. Baranova ◽  
S. N. Pchelina
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profile ◽  
Blood Lipid ◽  
Blood Lipid Profile ◽  
Study Objective ◽  
Therapy Effect ◽  
Atorvastatin Therapy

Study objective: to estimate efficiency of atorvastatin therapy in patients with type 2 diabetes mellitus (T2DM), who are the carrier of various genotypes Q192R paraoxonase gene 1 (PON1). 386 T2DM patients, who have not received statin therapy before, and 187 healthy people were examined. All those examined were exposed to blood lipid profile testing and molecular genetic research. The atorvastatin treatment group included 164 T2DM patients with abnormality of lipids, their blood lipid profile values were assessed before and after 3 months of the therapy. Blood lipid profile values did not differ in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism. Atorvastatin therapy decreased atherogenic lipoprotein levels in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism, but reduction degree in the carriers of different Q192R genotypes differed - in Q192Q bearers it was greater than in the bearers of Q192R genotype of gene PON1 (р = 0,031). Atorvastatin 3-months therapy revealed greater reduction of total cholesterol in the carriers of Q192Q genotype of gene 1 (PON1) than in the carriers of Q192R genotype of gene 1 (PON1).

Sign in / Sign up

Export Citation Format

Share Document